Business Wire
17 Mar 2026, 20:40 UTC · 35w ago
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
Impact · against what's priced in
The announcement of upcoming preliminary data for botensilimab and balstilimab in first-line MSS CRC creates a concrete catalyst event for Agenus. While the news is positive, the actual price movement will depend on the data presented in April, not the scheduling of the presentation.
- AGEN+0.20
No priced-in read yet





